hepatitis B

Latest Headlines

Latest Headlines

FDA panel concerned about safety of Dynavax's hep B vaccine

An FDA panel dealt a blow to Dynavax Technologies on Thursday, raising concerns about the safety of the company's hepatitis B vaccine.

Dynavax share price wilts after FDA panel snub

Dynavax Technologies ($DVAX) didn't get the safety nod it sought for its hepatitis B vaccine from FDA advisers Thursday, and its shares plummeted in extended trading. The Berkeley, CA-based biotech is seeking U.S. approval of the vaccine, Heplisav, which provides the developer its best shot at having a marketed product.

PerkinElmer snatches up Chinese molecular Dx outfit for $38M

PerkinElmer ($PKI) has become a much bigger player in China's molecular clinical diagnostics market with the wrap-up of its $38 million acquisition of Shanghai Haoyuan Biotech Co.

Startup biotech hauls in $23M A round for antiviral work

5AM Ventures and Canaan Partners have joined forces to lead a $23 million A round for a startup antiviral biotech based in Radnor, PA. Novira Therapeutics is developing capsid-targeting antivirals for hepatitis B and HIV.

MedMira gets $4.2M from U.S. Army for HIV, hepatitis Dx

The U.S. Army has tapped Canada's MedMira ($MIR) to develop rapid diagnostics that can detect HIV and hepatitis B and C, a deal worth $4.2 million.

In $69M IPO bid, GlobeImmune spotlights therapeutic vaccines

GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.

DKK1 could lead to a liver cancer blood test

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, and is usually a result of hepatitis B or C infection, or cirrhosis of the liver. Diagnosis is generally through CT or MRI scanning, but biomarkers could make diagnosis simpler, quicker, more effective and less expensive.

Cuban hepatitis B vax cuts disease

According to news reports, Cuba has eliminated viral hepatitis in its population under 15 through use of a vaccine against hepatitis B developed in Havana.

DNA biomarker pinpoints hep B liver cancers

Telomere length in circulating DNA could be a blood-based test for patients who will progress from hepatitis B infection to liver cancer.

Alnylam, Arrowhead join forces on RNAi tech

Alnylam Pharmaceuticals has sealed a new collaboration and licensing deal with Arrowhead Research Corp., giving it access to crucial drug delivery technology once owned by Swiss drug giant Roche.